CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 81 enrolled
Drug / intervention
Salmeterol xinafoate/fluticasone propionate combination +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00461500
NCT00461500Phase 4Completed
CompareCT.gov

Seretide 100 DK vs Flixotide 100 DK in IMT in Moderate Asthma in Adults on Static Lung Volumes (Mechanistic Study)

GlaxoSmithKline·interventional·Posted Apr 18, 2007·Updated Mar 3, 2017

In Brief

A Phase 4 clinical trial evaluating Salmeterol xinafoate/fluticasone propionate combination and Fluticasone propionate for Asthma. Completed, enrolled 81 participants.

Detailed Summary

This study will compare during 12 weeks, two treatment strategies for Initial Maintenance Therapy : fluticasone propionate alone or the salmeterol/fluticasone propionate combination in adults with moderate persistent asthma

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 18, 2007
Enrollment StartMar 1, 2007
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 19.2 years ago

Interventions

Salmeterol xinafoate/fluticasone propionate combinationdrug

SFC 100

Fluticasone propionatedrug

FP 100